How to Manage Estrogen on TRT

Your testosterone goes into your body and some of it becomes estrogen. That's not a malfunction. That's just how the system works.

The enzyme responsible is called aromatase, or more precisely CYP19A1, which is a cytochrome P450 enzyme that converts testosterone into estradiol through a three-step chemical reaction. It does this work in multiple tissues throughout the body, including your brain, bones, liver, and skin. But the place where most of the action happens in men is adipose tissue, meaning body fat. Roughly 80% of the estradiol circulating in a man's blood comes from this peripheral conversion in tissues, with only about 20% coming directly from the testes.

So when a man on TRT gets bloodwork back showing elevated estradiol, what that number is actually telling him is that aromatase is converting more testosterone than expected. And the next question, which most providers skip, is what's driving that conversion up.

Here's where the system starts to make sense. Aromatase doesn't run at a fixed rate. It responds to inputs. More of the right inputs means more enzyme activity, which means more estrogen production. The most common drivers are body fat, injection frequency, total dose, alcohol, insulin resistance, stress, sleep, inflammation, and genetics. Each of these is doing something specific to the conversion rate, and once you understand what, the path forward becomes obvious.

Start with body fat because it's the biggest lever most men are ignoring. Aromatase gene expression in adipose tissue is regulated by something called promoter I.4, and this promoter responds to glucocorticoids, inflammatory cytokines like TNF-alpha, and general weight gain. Research published in 2015 confirmed that weight gain and inflammation directly upregulate aromatase expression in male adipose tissue. This creates a compounding loop where more body fat means more aromatase enzyme, which means more testosterone converting to estrogen, which can drive further fat storage because estrogen at high levels encourages adipogenesis. You're not dealing with a fixed conversion rate. You're dealing with a rate that grows as the problem grows.

Injection frequency works through a different mechanism called substrate-driven conversion. Aromatase enzymes convert more when more raw material is available. When you inject a full week's dose of testosterone all at once, your blood levels spike significantly in the first 24 to 48 hours. Estradiol trails that peak by about one to two days, spiking around day three or four. That's when men tend to feel water retention, mood shifts, and nipple sensitivity. By day seven, testosterone has dropped considerably and estradiol follows it down, but you've already been riding that roller coaster for a week.

The half-life of testosterone cypionate is roughly 4.5 days, with a mean residence time of about 8.5 days. Splitting the same weekly dose into two injections reduces the peak-to-trough variance by roughly 30%. Daily injections reduce it further, getting closer to the body's natural production rhythm of about 6 to 7 milligrams per day. The total testosterone going in doesn't change. The total estrogen produced over the week may not change dramatically either. But the spikes flatten, and the symptoms that come from spiking are what send men and their doctors reaching for anastrozole in the first place.

Alcohol, insulin resistance, and chronic stress all feed aromatase expression through related pathways. Alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which is sex hormone-binding globulin, the protein that binds testosterone in the blood and determines how much of it is free and available for conversion. Higher body fat tends to lower SHBG, which raises free testosterone levels, which gives aromatase more substrate to work with. Cortisol from chronic stress drives aromatase expression through that same promoter I.4 pathway that responds to glucocorticoids. Poor sleep raises cortisol and inflammatory cytokines. The whole cluster of modern metabolic dysfunction feeds the same enzyme.

Now here's why managing all of this matters more than suppressing the enzyme directly. Estradiol is doing real protective work in the male body.

The clearest demonstration of this comes from a randomized controlled trial published in the New England Journal of Medicine in 2013. Researchers took 400 healthy men between 20 and 50 years old, suppressed their natural testosterone production with a drug called goserelin, and then randomized them to different testosterone doses either with or without anastrozole to block aromatization. When estrogen was blocked, sexual desire dropped significantly and erectile function declined significantly, and this happened even though testosterone was still present. Subcutaneous fat increased two to three times in the groups with suppressed estrogen. The study isolated estrogen's independent role by keeping testosterone in the picture and removing only the conversion to estradiol.

A separate randomized trial published in 2009 looked at 69 men over age 60 who took 1 milligram of anastrozole daily for 12 months versus a placebo. Spine bone mineral density decreased significantly in the anastrozole group. Estradiol dropped from around 15 to 12 pg/mL, a roughly 20% reduction, and that modest suppression produced measurable bone loss over a single year.

Estradiol in men is also tied to cardiovascular health through its effects on vascular smooth muscle and the endothelium, to brain function through local aromatization in neural tissue, and to bone density more strongly than testosterone itself according to the available data on bone turnover markers.

The clinical trap, then, looks like this. Weekly injection creates estradiol peaks. Patient reports symptoms. Provider prescribes anastrozole. Estrogen drops too low. Patient develops joint pain, erectile dysfunction, mood changes, and low-grade bone loss. Provider adjusts the anastrozole dose. Patient oscillates between too high and too low for months or years, on two drugs to manage a problem that injection frequency and lifestyle changes could have addressed without touching the enzyme at all.

If you are on TRT and your estradiol is elevated, the first thing to do is make sure the test is actually accurate. Standard immunoassay tests can cross-react with other steroids in men and give misleading numbers. The gold standard for male estradiol measurement is the LC-MS/MS test, which stands for liquid chromatography tandem mass spectrometry. This test is more specific and gives you a number you can actually act on. Typical ranges that clinicians look for are around 20 to 35 pg/mL at standard doses, with 40 to 60 considered acceptable at higher doses if symptoms are absent.

If the number is genuinely elevated and causing symptoms, start with the drivers before starting a drug. Injection frequency is the fastest adjustment with the most direct pharmacokinetic rationale. Body composition, alcohol, sleep, and stress are slower but they are changing the underlying enzyme environment rather than suppressing it.

It's worth being clear about one thing. The specific claim that switching from weekly to daily injections will eliminate the need for an AI in all cases has not been tested in a randomized trial. The mechanism is sound, the pharmacokinetics support the logic, and the clinical observation is consistent. But there is no head-to-head RCT comparing injection frequency as a primary strategy for estrogen management. Some men will have genetic variation in CYP19A1 expression that makes their conversion high regardless of frequency, and for those men an AI may genuinely be appropriate as a last resort rather than a first response.

Aromatase is not your enemy. It's an enzyme doing a job that your body depends on, and the question worth asking before you suppress it is what's making it work harder than you need it to.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness